BioInsights - BioInsights

CELL & GENE THERAPY INSIGHTS

Upcoming webinars

Analyzing full and empty AAV capsid ratio in less than 5 minutes

Analyzing full and empty AAV capsid ratio in less than 5 minutes

Zoe Anderson-Jenkins
15 April 2023
in 15
Days
Register
View all webinars

Latest Articles

A fresh look at analytical methods for vaccines

A fresh look at analytical methods for vaccines

8 March 2023
From cells to purified capsids: How to develop a scalable rAAV process

From cells to purified capsids: How to develop a scalable rAAV process

Asa McWhirter
17 June 2022
Quantifying the tumor microenvironment: what is the next step to advance cancer immunotherapy?

Quantifying the tumor microenvironment: what is the next step to advance cancer immunotherapy?

Alexander EGGERMONT
29 March 2022
Quantifying the tumor microenvironment: what is the next step to advance cancer immunotherapy?

Quantifying the tumor microenvironment: what is the next step to advance cancer immunotherapy?

29 March 2022
Application Note
Regulatory & supply chain implications for plasmids as critical starting materials in the manufacture of viral vector gene therapy products

Regulatory & supply chain implications for plasmids as critical starting materials in the manufacture of viral vector gene therapy products

14 March 2022
Yesterday, today and tomorrow: the evolving landscape of gene therapy manufacturing and process development

Yesterday, today and tomorrow: the evolving landscape of gene therapy manufacturing and process development

10 March 2022
Innovator Insight
Yesterday, today and tomorrow: the evolving landscape of gene therapy manufacturing and process development

Yesterday, today and tomorrow: the evolving landscape of gene therapy manufacturing and process development

David Knop
10 February 2022
Commentary
Outcomes from a cell viability workshop: fit-for-purpose considerations for cell viability measurements for cellular therapeutic products

Outcomes from a cell viability workshop: fit-for-purpose considerations for cell viability measurements for cellular therapeutic products

L Pierce, S Sarkar, B Lin et al.
8 February 2022
Commentary
Expression systems for viral vector production: advantages of the Sf9 baculovirus system and simple solutions to address its specific analytical challenges

Expression systems for viral vector production: advantages of the Sf9 baculovirus system and simple solutions to address its specific analytical challenges

Yi Fang Lee, Srinath Ranganath
27 January 2022
Innovator Insight

Channel content

Quantifying the tumor microenvironment: what is the next step to advance cancer immunotherapy?

Quantifying the tumor microenvironment: what is the next step to advance cancer immunotherapy?

Alexander EGGERMONT
29 March 2022
Quantifying the tumor microenvironment: what is the next step to advance cancer immunotherapy?

Quantifying the tumor microenvironment: what is the next step to advance cancer immunotherapy?

29 March 2022
Application Note
View channel
Yesterday, today and tomorrow: the evolving landscape of gene therapy manufacturing and process development

Yesterday, today and tomorrow: the evolving landscape of gene therapy manufacturing and process development

David Knop
10 February 2022
Commentary
Outcomes from a cell viability workshop: fit-for-purpose considerations for cell viability measurements for cellular therapeutic products

Outcomes from a cell viability workshop: fit-for-purpose considerations for cell viability measurements for cellular therapeutic products

L Pierce, S Sarkar, B Lin et al.
8 February 2022
Commentary
Expression systems for viral vector production: advantages of the Sf9 baculovirus system and simple solutions to address its specific analytical challenges

Expression systems for viral vector production: advantages of the Sf9 baculovirus system and simple solutions to address its specific analytical challenges

Yi Fang Lee, Srinath Ranganath
27 January 2022
Innovator Insight
View channel
Regulatory & supply chain implications for plasmids as critical starting materials in the manufacture of viral vector gene therapy products

Regulatory & supply chain implications for plasmids as critical starting materials in the manufacture of viral vector gene therapy products

14 March 2022
Scalable AAV manufacturing: addressing challenges across the workflow

Scalable AAV manufacturing: addressing challenges across the workflow

editor
18 January 2021
Innovator Insight
1Viral vector production process intensification: analytics, automation, in-line testing, and more

1Viral vector production process intensification: analytics, automation, in-line testing, and more

M DiBiasio-White, F Gerner, J Tate et al.
18 January 2021
Expert Roundtable Video
View channel
A year like no other: reflecting on the challenges of 2020, and looking to regain momentum for cell and gene therapy in 2021

A year like no other: reflecting on the challenges of 2020, and looking to regain momentum for cell and gene therapy in 2021

Peter Marks
8 January 2021
Interview
Exosomes as therapeutics and drug delivery vehicles: global regulatory perspectives

Exosomes as therapeutics and drug delivery vehicles: global regulatory perspectives

Shaun Stapleton
17 December 2020
Perspective
How to standardize quality requirements of raw materials

How to standardize quality requirements of raw materials

Bernd Leistler
1 December 2020
Editorial
View channel
Abbreviated in-house qualification of real time mycoplasma detection kit

Abbreviated in-house qualification of real time mycoplasma detection kit

Sowmya Viswanathan
7 January 2021
On Demand Webinar
Celyad Oncology’s case study: validation approach for accelerated mycoplasma testing

Celyad Oncology’s case study: validation approach for accelerated mycoplasma testing

Sarah Snykers
7 January 2021
On Demand Webinar
Viral vector manufacturing and transfection efficiency in the iCELLis<sup>®</sup> bioreactor system

Viral vector manufacturing and transfection efficiency in the iCELLis® bioreactor system

R Legmann, F Collard, A Nyamay’Antu
17 December 2020
Interview
View channel
Guiding America througha pandemic

Guiding America througha pandemic

A Fauci, C Yilmaz, C Yi et al.
19 May 2022
Interview
An innovative collaborative approach towards the development of gene therapies for rare and ultra-rare genetic disorders of the CNS

An innovative collaborative approach towards the development of gene therapies for rare and ultra-rare genetic disorders of the CNS

Leszek Lisowski, Wendy Gold
23 December 2020
Interview
An innovative collaborative approach towards the development of gene therapies for rare and ultra-rare genetic disorders of the CNS

An innovative collaborative approach towards the development of gene therapies for rare and ultra-rare genetic disorders of the CNS

Leszek Lisowski, Wendy Gold
22 December 2020
Podcast
View channel
What to expect in 2021: seven cell and gene therapy commercialization trends

What to expect in 2021: seven cell and gene therapy commercialization trends

Heidi Hagen
10 December 2020
Innovator Insight
Driving disruptive innovation in the ATMP field

Driving disruptive innovation in the ATMP field

Kerstin Papenfuss
6 October 2020
Interview
Boldly de-risking development of impactful cell and gene therapies: the California Stem Cell Agency’s $3B funding model

Boldly de-risking development of impactful cell and gene therapies: the California Stem Cell Agency’s $3B funding model

S Patel, S Talib, M Millan
5 October 2020
Commentary
View channel